U.S. Markets close in 12 mins

Vapotherm, Inc. (VAPO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
30.70-1.15 (-3.61%)
As of 3:48PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close31.85
Open31.48
Bid30.78 x 800
Ask30.87 x 1000
Day's Range30.30 - 32.03
52 Week Range6.86 - 54.42
Volume508,411
Avg. Volume686,585
Market Cap785.005M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.23
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.33
  • Vapotherm Announces Appointment of Donald Spence to Board of Directors and the Resignations of Craig Reynolds and Geoff Pardo
    Business Wire

    Vapotherm Announces Appointment of Donald Spence to Board of Directors and the Resignations of Craig Reynolds and Geoff Pardo

    Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to the Company’s Board of Directors. Mr. Spence will serve as a member and chair of the Compensation Committee, and as a member of the Audit Committee. The Board of Directors unanimously voted to appoint Mr. Spence to fill these positions, effective October 21, 2020.

  • Vapotherm Announces Closing of Debt Refinancing
    Business Wire

    Vapotherm Announces Closing of Debt Refinancing

    Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it has entered into a loan and security agreement with CIBC Innovation Banking that provides the Company with up to $52 million in debt financing through a combination of a term loan facility and a revolving credit facility. Proceeds of the facilities will be used to repay the Company’s existing revolving loan facility and term loan facility.

  • Vapotherm to Report Third Quarter 2020 Financial Results
    Business Wire

    Vapotherm to Report Third Quarter 2020 Financial Results

    Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of Vapotherm’s proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 4, 2020. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.